A detailed history of Brinker Capital Investments, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Brinker Capital Investments, LLC holds 15,877 shares of REGN stock, worth $12.1 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
15,877
Previous 19,998 20.61%
Holding current value
$12.1 Million
Previous $13.8 Million 16.85%
% of portfolio
0.23%
Previous 0.28%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

SELL
$705.89 - $766.39 $2.91 Million - $3.16 Million
-4,121 Reduced 20.61%
15,877 $11.5 Million
Q3 2022

Nov 01, 2022

SELL
$573.97 - $724.32 $277,801 - $350,570
-484 Reduced 2.36%
19,998 $13.8 Million
Q2 2022

Jul 18, 2022

SELL
$548.35 - $738.84 $98,154 - $132,252
-179 Reduced 0.87%
20,482 $12.1 Million
Q1 2022

May 16, 2022

SELL
$595.12 - $698.43 $3.27 Million - $3.84 Million
-5,492 Reduced 21.0%
20,661 $14.4 Million
Q4 2021

Feb 08, 2022

SELL
$543.48 - $670.97 $4.35 Million - $5.38 Million
-8,011 Reduced 23.45%
26,153 $16.5 Million
Q3 2021

Nov 08, 2021

BUY
$574.03 - $680.96 $440,855 - $522,977
768 Added 2.3%
34,164 $19.1 Million
Q2 2021

Aug 03, 2021

BUY
$472.8 - $558.54 $2.71 Million - $3.21 Million
5,741 Added 20.76%
33,396 $18.7 Million
Q1 2021

May 12, 2021

BUY
$446.73 - $548.2 $12.4 Million - $15.2 Million
27,655 New
27,655 $13.1 Million
Q4 2020

Feb 16, 2021

SELL
$478.3 - $607.98 $6.54 Million - $8.31 Million
-13,676 Closed
0 $0
Q3 2020

Dec 03, 2020

BUY
$544.75 - $658.21 $7.45 Million - $9 Million
13,676 New
13,676 $7.66 Million
Q1 2020

May 13, 2020

SELL
$336.18 - $494.43 $1,008 - $1,483
-3 Closed
0 $0
Q4 2019

Feb 06, 2020

BUY
$274.13 - $376.51 $822 - $1,129
3 New
3 $1,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.7B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Brinker Capital Investments, LLC Portfolio

Follow Brinker Capital Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brinker Capital Investments, LLC with notifications on news.